|Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|Outline of Final Research Achievements
In this study, I focused on Clec4A4 molecule, which is involved in suppression of immune response during cancer progression, and attempted functional identification of a novel dendritic cell immune checkpoint that negatively regulates cancer immune responses. As a result, tumor progression of melanoma was suppressed in the tumor-bearing Clec4A4 deficient mice as compared with the tumor-bearing wild type mice. This result suggest that Clec4A4 functions as an activation regulatory molecule of dendritic cells and is a new immune checkpoint in the cancer immune responses.